<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37799470</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2234-943X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in oncology</Title><ISOAbbreviation>Front Oncol</ISOAbbreviation></Journal><ArticleTitle>The safety and efficacy of PD-1 inhibitors in patients with advanced cancers and HIV/AIDS in China.</ArticleTitle><Pagination><StartPage>1248790</StartPage><MedlinePgn>1248790</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1248790</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fonc.2023.1248790</ELocationID><Abstract><AbstractText>Purpose-Immunotherapy has revolutionized&#xa0;cancer&#xa0;therapy, becoming the standard&#xa0;of&#xa0;care for various malignancy treatments. Human immunodeficiency virus (HIV) patients, however, are an underserved group with limited access to clinical trials and cancer therapy. This study was to evaluate the safety and efficacy of programmed cell death 1 (PD - 1) inhibitors in patients with advanced cancer and HIV/acquired immunodeficiency syndrome (AIDS). Methods and Materials-We performed a prospective, open-label, nonrandomized, phase 1 single center study. Patients with advanced cancer and HIV/AIDS received the treatment of PD - 1 inhibitors (camrelizumab, 200 mg, administered intravenously every 3 weeks), along with combination antiretroviral therapy (cART) for HIV. Results-Sixteen participants (12 men and 4 women; median age, 46.5 (29 - 78) years) were enrolled; 1 had non - Hodgkin lymphoma (NHL), and 15 had non - AIDS - defining cancers. Safety was observed over 130 cycles of treatment with camrelizumab. Most treatment-emergent adverse events at least possibly attributed to camrelizumab were grade 1 or 2, including reactive cutaneous capillary endothelial proliferation (RCCEP) (9 participants), hearing loss (1 participant), hypophysitis (1 participant). 3 participants experienced hemorrhage due to poor performance status. HIV was controlled in all participants. Best tumor responses included 3 complete response, 5 partial response, 2 stable disease, and 6 progressive disease. The 2 years progression-free survival (PFS) was 67.0% (95% CI: -0.05, 0.00) and overall survival (OS) was 55.3% (95% CI: -0.05, 0.01) for the 16 patients who had received camrelizumab. Conclusions-This study demonstrates that camrelizumab treatment in patients with advanced cancers and HIV/AIDS was feasible and the clinical outcomes were acceptable.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Xiong, Mo, Yan, Wang, Zhuang, Ma, Chen, Deng, Xiong, Deng and Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Pingzheng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of AIDS Prevention and Cure, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yajun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre of AIDS Prevention and Cure, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>ABSL-III Laboratory at the Center for Animal Experiment, Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Zhiyong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Clinical Cancer Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yongxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of AIDS Prevention and Cure, Zhongnan Hospital of Wuhan University, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Oncol</MedlineTA><NlmUniqueID>101568867</NlmUniqueID><ISSNLinking>2234-943X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">PD-1</Keyword><Keyword MajorTopicYN="N">camrelizumab</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>6</Day><Hour>3</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37799470</ArticleId><ArticleId IdType="pmc">PMC10547588</ArticleId><ArticleId IdType="doi">10.3389/fonc.2023.1248790</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges. Curr HIV/AIDS Rep (2020) 17(1):26&#x2013;34. doi: 10.1007/s11904-019-00478-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-019-00478-x</ArticleId><ArticleId IdType="pmc">PMC6989417</ArticleId><ArticleId IdType="pubmed">31939111</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med (2018) 378(11):1029&#x2013;1041. doi: 10.1056/NEJMra1615896</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1615896</ArticleId><ArticleId IdType="pmc">PMC6890231</ArticleId><ArticleId IdType="pubmed">29539283</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges &#xc1;H. Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS (2017) 12(1):12&#x2013;19. doi: 10.1097/COH.0000000000000334</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000334</ArticleId><ArticleId IdType="pmc">PMC5244841</ArticleId><ArticleId IdType="pubmed">27755153</ArticleId></ArticleIdList></Reference><Reference><Citation>Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, et al. . Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. (2019) 6(2):e93&#x2013;e104. doi: 10.1016/S2352-3018(18)30295-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(18)30295-9</ArticleId><ArticleId IdType="pmc">PMC6589140</ArticleId><ArticleId IdType="pubmed">30683625</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan KL, Wall KC, Bartlett JA, Suneja G. Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining Malignancies. Cancer. (2019) 125(6):843&#x2013;853. doi: 10.1002/cncr.31838</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.31838</ArticleId><ArticleId IdType="pmc">PMC6488220</ArticleId><ArticleId IdType="pubmed">30645766</ArticleId></ArticleIdList></Reference><Reference><Citation>Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, et al. . Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: a multinational prospective cohort study. Ann Intern Med (2021) 174(6):768&#x2013;776. doi: 10.7326/M20-5226</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5226</ArticleId><ArticleId IdType="pubmed">33721519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung IY, Rupasinghe D, Woolley I, O&#x2019;Connor CC, Giles M, Azwa RI, et al. . Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the treat Asia HIV observational database (TAHOD) and Australian HIV observational database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc (2019) 22:e25219. doi: 10.1002/jia2.25219</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25219</ArticleId><ArticleId IdType="pmc">PMC6322485</ArticleId><ArticleId IdType="pubmed">30615271</ArticleId></ArticleIdList></Reference><Reference><Citation>Uldrick TS, Adams SV, Fromentin R, Roche M, Fling SP, Gon&#xe7;alves PH, et al. . Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci Transl Med (2022) 14(629):eabl3836. doi: 10.1126/scitranslmed.abl3836</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl3836</ArticleId><ArticleId IdType="pmc">PMC9014398</ArticleId><ArticleId IdType="pubmed">35080914</ArticleId></ArticleIdList></Reference><Reference><Citation>Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf. (2019) 42(2):281&#x2013;294. doi: 10.1007/s40264-018-0774-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-018-0774-8</ArticleId><ArticleId IdType="pubmed">30649742</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. . Camrelizumab versus investigator&#x2019;s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol (2020) 21(6):832&#x2013;842. doi: 10.1016/S1470-2045(20)30110-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30110-8</ArticleId><ArticleId IdType="pubmed">32416073</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. . Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol (2020) 21(4):571&#x2013;580. doi: 10.1016/S1470-2045(20)30011-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30011-5</ArticleId><ArticleId IdType="pubmed">32112738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. . Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non- squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med (2021) 9(3):305&#x2013;314. doi: 10.1016/S2213-2600(20)30365-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30365-9</ArticleId><ArticleId IdType="pubmed">33347829</ArticleId></ArticleIdList></Reference><Reference><Citation>Guaitoli G, Baldessari C, Maur M, Mussini C, Meschiari M, Barbieri F, et al. . Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. Crit Rev Oncol Hematol (2020) 145:102836. doi: 10.1016/j.critrevonc.2019.102836</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2019.102836</ArticleId><ArticleId IdType="pubmed">31918216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, et al. . Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non-small cell lung cancer. J Thorac Oncol (2018) 13(7):1037&#x2013;1042. doi: 10.1016/j.jtho.2018.03.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2018.03.031</ArticleId><ArticleId IdType="pubmed">29631035</ArticleId></ArticleIdList></Reference><Reference><Citation>Spano JP, Veyri M, Gobert A, Guihot A, Perr&#xe9; P, Kerjouan M, et al. . Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience. Aids (2019) 33(11):F13&#x2013;F19. doi: 10.1097/QAD.0000000000002298</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002298</ArticleId><ArticleId IdType="pubmed">31259762</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau JSY, McMahon JH, Gubser C, Solomon A, Chiu CYH, Dantanarayana A, et al. . The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. Aids. (2021) 35(10):1631&#x2013;1636. doi: 10.1097/QAD.0000000000002919</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002919</ArticleId><ArticleId IdType="pmc">PMC8286319</ArticleId><ArticleId IdType="pubmed">33859108</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45(2):228&#x2013;247. doi: 10.1016/j.ejca.2008.10.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2008.10.026</ArticleId><ArticleId IdType="pubmed">19097774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. . Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. (2016) 128(21):2489&#x2013;2496. doi: 10.1182/blood-2016-05-718528</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-05-718528</ArticleId><ArticleId IdType="pubmed">27574190</ArticleId></ArticleIdList></Reference><Reference><Citation>Uldrick TS, Gon&#xe7;alves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, et al. . Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer - a phase 1 study. JAMA Oncol (2019) 5(9):1332&#x2013;1339. doi: 10.1001/jamaoncol.2019.2244</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2019.2244</ArticleId><ArticleId IdType="pmc">PMC6547135</ArticleId><ArticleId IdType="pubmed">31154457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cao M, Moran T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, et al. . Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 Infection: the phase 2 DURVAST study. JAMA Oncol (2020) 6(7):1063&#x2013;1067. doi: 10.1001/jamaoncol.2020.0465</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2020.0465</ArticleId><ArticleId IdType="pmc">PMC7146525</ArticleId><ArticleId IdType="pubmed">32271353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in Patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol (2019) 5(7):1049&#x2013;1054. doi: 10.1001/jamaoncol.2018.6737</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2018.6737</ArticleId><ArticleId IdType="pubmed">30730549</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. Cancer immunotherapy of patients with HIV infection. Clin Translat Oncol (2019) 21(6):713&#x2013;720. doi: 10.1007/s12094-018-1981-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12094-018-1981-6</ArticleId><ArticleId IdType="pubmed">30446984</ArticleId></ArticleIdList></Reference><Reference><Citation>Makuku R, Seyedmirzaei H, Tantuoyir MM, Rodr&#xed;guez-Rom&#xe1;n E, Albahash A, Mohamed K, et al. . Exploring the application of immunotherapy against HIV infection in the setting of Malignancy: A detailed review article. Int Immunopharmacol. (2022) 105:108580. doi: 10.1016/j.intimp.2022.108580</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108580</ArticleId><ArticleId IdType="pubmed">35121225</ArticleId></ArticleIdList></Reference><Reference><Citation>Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, et al. . CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS2 and elderly population. Eur J Cancer. (2020) 127:160&#x2013;172. doi: 10.1016/j.ejca.2019.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2019.11.019</ArticleId><ArticleId IdType="pubmed">32028209</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J, et al. . Pembrolizumab in patients with non-smallcell lung cancer of performans status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med (2020) 8(9):895&#x2013;904. doi: 10.1016/S2213-2600(20)30033-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30033-3</ArticleId><ArticleId IdType="pubmed">32199466</ArticleId></ArticleIdList></Reference><Reference><Citation>Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, et al. . Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non-small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153). J Thorac Oncol (2019) 14(9):1628&#x2013;1639. doi: 10.1016/j.jtho.2019.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2019.05.010</ArticleId><ArticleId IdType="pubmed">31121324</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlesi F, Audigier-Valette C, Felip E, Ciuleanu TE, Rosario Garc&#xed;a Campelo M, et al. . CheckMate 817: first-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. J Thorac Oncol (2019) 14(10):S214&#x2013;S215. doi: 10.1016/j.jtho.2019.08.424</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2019.08.424</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, et al. . Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: a systematic review. Medicine. (2020) 99:e19013. doi: 10.1097/MD.0000000000019013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000019013</ArticleId><ArticleId IdType="pmc">PMC7004734</ArticleId><ArticleId IdType="pubmed">32000444</ArticleId></ArticleIdList></Reference><Reference><Citation>Gounant V, Lavol&#xe9; A, Quoix E. Ongoing challenges of using immunotherapy in special populations: poor performance status patients, elderly patients, and people living with HIV. Lung Cancer. (2020) 145:71&#x2013;75. doi: 10.1016/j.lungcan.2020.04.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2020.04.025</ArticleId><ArticleId IdType="pubmed">32416431</ArticleId></ArticleIdList></Reference><Reference><Citation>Marur S, Singh H, Mishra-Kalyani P, Larkins E, Keegan P, Sridhara R, et al. . FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. Semin Oncol (2018) 45(4):220&#x2013;225. doi: 10.1053/j.seminoncol.2018.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2018.08.007</ArticleId><ArticleId IdType="pubmed">30391014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>